| | | | | | | | | | | | | | | | |
| |
| Issue Date FY: 2024 ( Subtotal = $63,745,380 ) (Continued on the next page) |
| 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | U01CA275886 | Identifying and targeting collateral lethal vulnerabilities in cancers | 000 | 2 | NIH | 4/3/2024 | $918,686 |
| 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA269140 | Targeting the LIFR-LCN2 pathway to improve liver cancer therapy | 001 | 2 | NIH | 4/17/2024 | $24,007 |
| 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA269140 | Targeting the LIFR-LCN2 pathway to improve liver cancer therapy | 000 | 2 | NIH | 12/12/2023 | $432,117 |
| 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R21CA259749 | A combination strategy to target pathophysiology of chronic lymphocytic leukemia | 001 | 2 | NIH | 4/17/2024 | $11,361 |
| 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R21CA259749 | A combination strategy to target pathophysiology of chronic lymphocytic leukemia | 000 | 2 | NIH | 1/15/2024 | $204,485 |
| 2024 | 2024 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | R01HL163857 | Premature aging disorders, metabolites, and atherosclerosis | 001 | 2 | NIH | 11/16/2023 | $647,209 |
| 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA276235 | Cis-aconitate decarboxylase (ACOD1) in PMN-MDSC and prostate cancer progression | 001 | 2 | NIH | 4/16/2024 | $18,529 |
| 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA276235 | Cis-aconitate decarboxylase (ACOD1) in PMN-MDSC and prostate cancer progression | 000 | 2 | NIH | 12/12/2023 | $333,518 |
| 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA269565 | The Role of HIF2 in Pancreatic Ductal Adenocarcinoma | 002 | 2 | NIH | 4/17/2024 | $28,635 |
| 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA269565 | The Role of HIF2 in Pancreatic Ductal Adenocarcinoma | 003 | 2 | NIH | 4/22/2024 | $3,458 |
| 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA269565 | The Role of HIF2 in Pancreatic Ductal Adenocarcinoma | 000 | 2 | NIH | 2/6/2024 | $515,400 |
| 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA269565 | The Role of HIF2 in Pancreatic Ductal Adenocarcinoma | 001 | 2 | NIH | 2/9/2024 | $62,227 |
| 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA275712 | Deciphering pathways involved in topoisomerase II turnover | 001 | 2 | NIH | 4/17/2024 | $25,149 |
| 2024 | 2024 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | R01CA275712 | Deciphering pathways involved in topoisomerase II turnover | 000 | 2 | NIH | 11/29/2023 | $452,669 |
| 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA280827 | Next Generation Engineered NK Cells for Lymphoma Patients after CD19 CAR-T Cell Failure. | 001 | 2 | NIH | 4/17/2024 | $18,529 |
| 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA280827 | Next Generation Engineered NK Cells for Lymphoma Patients after CD19 CAR-T Cell Failure. | 000 | 2 | NIH | 2/21/2024 | $333,518 |
| 2024 | 2024 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | R34AT012360 | Randomized controlled trial to test feasibility of a culturally adapted meditation-based support intervention for Black patients dealing with advanced cancer | 000 | 2 | NIH | 11/17/2023 | $218,700 |
| 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R21CA277283 | First-in-Human Imaging of Innate Immunity Activation with a Redox-Tuned PET Reporter | 001 | 2 | NIH | 4/22/2024 | $9,465 |
| 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R21CA277283 | First-in-Human Imaging of Innate Immunity Activation with a Redox-Tuned PET Reporter | 000 | 2 | NIH | 3/8/2024 | $170,405 |
| 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R21CA277332 | Identifying Novel Radiation Sensitizers in Cervical Cancer | 003 | 2 | NIH | 4/17/2024 | $9,465 |
| 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R21CA277332 | Identifying Novel Radiation Sensitizers in Cervical Cancer | 002 | 2 | NIH | 2/19/2024 | $0 |
| 2024 | 2024 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | R21CA277332 | Identifying Novel Radiation Sensitizers in Cervical Cancer | 001 | 2 | NIH | 11/16/2023 | $57,406 |
| 2024 | 2024 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | R21CA277332 | Identifying Novel Radiation Sensitizers in Cervical Cancer | 000 | 2 | NIH | 11/15/2023 | $170,405 |
| 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R50CA275822 | A radiation oncology clinician scientist devoted to building an inclusive clinical research program in an integrated academic satellite network in service to the National Cancer Institute | 000 | 2 | NIH | 4/3/2024 | $86,702 |
| 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA271223 | Dissemination and implementation of DIGEST? as an evidence-based measurement tool for dysphagia in cancer | 001 | 2 | NIH | 4/17/2024 | $32,198 |
| 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA271223 | Dissemination and implementation of DIGEST? as an evidence-based measurement tool for dysphagia in cancer | 000 | 2 | NIH | 2/9/2024 | $579,570 |
| 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA260661 | Metabolic basis of ARID1A-mutated ovarian cancer | 001 | 3 | NIH | 4/17/2024 | $24,484 |
| 2024 | 2024 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | R01CA260661 | Metabolic basis of ARID1A-mutated ovarian cancer | 000 | 3 | NIH | 11/15/2023 | $440,741 |
| 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01DE030875 | Functional roles of GOF TP53 mutations in metastasis and immunosuppression of head and neck cancers | 000 | 3 | NIH | 2/13/2024 | $500,532 |
| 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R37CA261952 | Role of the pro-inflammatory omental microenvironment in ovarian cancer progression | 000 | 3 | NIH | 4/23/2024 | $408,231 |
| 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | K08CA263298 | Skin Cancer Risks and Risk Prediction in Patients with Actinic Keratosis | 000 | 3 | NIH | 3/4/2024 | $260,582 |
| 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA278967 | CRACD-controlled cell plasticity and small cell lung cancer | 000 | 1 | NIH | 12/27/2023 | $599,733 |
| 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R21CA277152 | Preclinical studies of non-nucleoside DNMT3A/3B inhibitors | 000 | 1 | NIH | 12/26/2023 | $227,205 |
| 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R21CA288804 | A Novel Strategy of Targeting Transmembrane Protein to Improve KRAS-targeted Therapy | 000 | 1 | NIH | 2/28/2024 | $214,399 |
| 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | S10OD036252 | Nikon CSU W1 SoRa Super Resolution Spinning Disk Confocal Microscope with Photo-Stimulation and Photo-Ablation | 000 | 1 | NIH | 4/22/2024 | $897,557 |
| 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R37CA288448 | Mechanisms of Hyperprogression to Immunotherapy in SMARCB1-Deficient Renal Malignancies | 000 | 1 | NIH | 3/4/2024 | $672,300 |
| 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA288617 | TROP2-Directed CAR-NK Cells for the Immunotherapy of Pancreatic Cancer | 000 | 1 | NIH | 4/5/2024 | $370,575 |
| 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R03CA289563 | Effect of SIRPalpha mismatch on the outcomes of allogeneic hematopoietic stem cell transplantation (HSCT) from an HLA matched related donor | 000 | 1 | NIH | 3/8/2024 | $81,000 |
| 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA279452 | Targeting non-small cell lung cancer cells and the adverse tumor microenvironment with a small-molecule STAT3 inhibitor | 000 | 1 | NIH | 12/19/2023 | $672,297 |
| 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R21CA273661 | A novel uterine leiomyosarcoma mouse model for therapeutic development | 000 | 1 | NIH | 1/11/2024 | $227,205 |
| 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R13CA287350 | Cancer Neuroscience - An Emerging Hallmark | 000 | 1 | NIH | 2/1/2024 | $15,000 |
| 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R25DA059907 | Supporting Tobacco-Related Ongoing Education and Research (STRONGER) Scholar Program | 000 | 1 | NIH | 3/20/2024 | $288,778 |
| 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R21CA274085 | Impact of tamoxifen treatment on neutrophils in breast cancer patients | 000 | 1 | NIH | 3/7/2024 | $191,704 |
| 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA289456 | Targeting the gut microbiome to inhibit melanoma lymph node metastases | 000 | 1 | NIH | 4/26/2024 | $530,612 |
| 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01GM152497 | Computational toolkit for robust detection of genomic variation in human leukocyte antigen genes | 000 | 1 | NIH | 3/18/2024 | $307,835 |
| 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R03DE033550 | Probabilistic Deep Learning Cervical Lymph-Node Auto-Segmentation For Imaging-enhanced Evaluation of Extracapsular Extension Risk (PDL-CLASIFIER) | 000 | 1 | NIH | 3/19/2024 | $162,000 |
| 2024 | 2024 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | K22CA279077 | Enhancing the efficacy of immunotherapy by optimal use of SMAC mimetics | 000 | 1 | NIH | 11/14/2023 | $192,240 |
| 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA278938 | Comparative Effectiveness of Sequential Pharmacotherapeutic Strategies and Virtually Delivered Treatment to Optimize Smoking Cessation | 001 | 1 | NIH | 12/22/2023 | $0 |
| 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA278938 | Comparative Effectiveness of Sequential Pharmacotherapeutic Strategies and Virtually Delivered Treatment to Optimize Smoking Cessation | 000 | 1 | NIH | 12/20/2023 | $923,199 |
|